Reverse activity-based protein profiling identifies a class of METTL16 covalent inhibitors
Available online 28 April 2026
Covalent inhibition of disease-associated proteins offers a rapid and robust strategy for drug discovery. METTL16, an RNA N6-methyladenosine (m6A) methyltransferase, plays oncogenic roles in multiple...